Oatly Group AB Announces Results of 2024 Annual General Meeting
MALMÖ, Sweden, May 15, 2024 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original […]
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
Key Highlights: Second research site selected to enhance enrollment in the Phase 2a clinical trial for Cholesterol Efflux MediatorTM VAR […]
The Real Good Food Company to Participate in the 24th Annual B. Riley Institutional Investor Conference
CHERRY HILL, N.J., May 15, 2024 (GLOBE NEWSWIRE) — The Real Good Food Company, Inc. (NASDAQ: RGF) (“Real Good Foods” […]
Airship AI Reports First Quarter 2024 Financial Results
Strong First Quarter 2024 Net Revenues of $10.6 Million Support Fiscal Year 2024 Triple-Digit Revenue Growth & Positive Cash Flow […]
Yield10 Bioscience Announces Delisting from Nasdaq
WOBURN, Mass., May 15, 2024 (GLOBE NEWSWIRE) — Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, […]
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
MIAMI, FL, May 15, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on […]
Atossa Therapeutics Announces Last Patient, Last Dose in its Phase 2 Karisma-Endoxifen Clinical Trial
SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the […]
Genasys Receives $2.7 Million U.S. Navy Order for LRAD Maritime Systems
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in Protective Communications, today announced […]
FTC Solar Announces New Sales and Leadership Appointments
AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) — FTC Solar, Inc. (Nasdaq: FTCI), a leading provider of solar tracker systems, software, […]
Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results
— Received Rare Pediatric Disease and Orphan Drug Designation for Duchenne musculardystrophy (Duchenne) gene therapy candidate SGT-003 with patient dosing […]
